Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study

被引：0
|
作者：
Kaseb, Ahmed Omar
Cabrera, Roniel
Iyer, Renuka
Parikh, Neehar
Kalman, Richard
Ozgurdal, Kirhan
Khan, Javeed
Babajanyan, Svetlana
Finn, Richard S.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Florida, Gainesville, FL USA
[3] Roswell Pk Canc Inst, Buffalo, NY USA
[4] Univ Michigan Med, Ann Arbor, MI USA
[5] Einstein Healthcare Network, Philadelphia, PA USA
[6] Bayer, Basel, Switzerland
[7] Bayer PLC, Reading, Berks, England
[8] Bayer Healthcare, Whippany, NJ USA
[9] UCLA Med Ctr, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16114
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.
    Merle, Philippe
    Lim, Ho Yeong
    Finn, Richard S.
    Ikeda, Masafumi
    Kudo, Masatoshi
    Frenette, Catherine T.
    Masi, Gianluca
    Kim, Yoon Jun
    Gerolami, Rene
    Kurosaki, Masayuki
    Numata, Kazushi
    Kluempen, Heinz-Josef
    Zebger-Gong, Hong
    Fiala-Buskies, Sabine
    Ozgurdal, Kirhan
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study
    Ross, Paul J.
    Ma, Yuk Ting
    Palmer, Daniel H.
    Lythgoe, Mark Peter
    Merrick, Sophie
    Samson, Adel
    Rao, Ankit Rohit
    Basu, Bristi
    Prasad, Debi
    Dhillon, Tony
    Lau, David
    Darby, Suzanne
    Orr, James
    Margetts, Jane
    Hubner, Richard
    Baijal, Shobhit
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Lee, Lennard
    Thillai, Kiruthikah
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
    Takehara, T.
    Kato, N.
    Aikata, H.
    Kuzuya, T.
    Hiasa, Y.
    Nakamura, S.
    Yamamoto, K.
    Morimoto, N.
    Sakamori, R.
    Kawamura, Y.
    Tsuchiya, K.
    Ueshima, K.
    Hiraoka, A.
    Nakano, M.
    Kokudo, N.
    Furuse, J.
    Moriguchi, M.
    Yamashita, T.
    Ikeda, M.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1480 - S1481
  • [24] The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study
    Hu, Li
    Yang, Zhoutian
    Yang, Zhenyun
    Peng, Wei
    Tang, Xiang
    Ye, Zhiwei
    Wang, Juncheng
    Fu, Yizhen
    Hu, Dandan
    Chen, Minshan
    Zhang, Yaojun
    Chen, Jinbin
    HEPATOLOGY INTERNATIONAL, 2024,
  • [25] Real-world treatment patterns among US adults with unresectable hepatocellular carcinoma (uHCC) eligible for locoregional therapy (LRT).
    Ramakrishnan, Karthik
    Hurwitz, Kathleen
    Dubrovsky, Leonid
    Estenson, Kasey
    Hendrickson, Kayla
    Jackman, Leah
    Bowden, Laney
    Siegel, Abby B.
    Fried, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 547 - 547
  • [26] Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.
    Xiong, Yiqi
    Gao, WenFeng
    Long, Jiang
    Hu, CaiXia
    Yuan, ChunWang
    Sun, Yu
    Shi, QinSheng
    Sun, Bin
    Zhang, YingHua
    Cui, XiongWei
    Hao, MeiJun
    Li, Jianjun
    Zhang, Yonghong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Atezolizumab plus bevacizumab (A plus B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network
    Cosgrove, David
    Tan, Amie
    Osterland, Andrew
    Hernandez, Sairy
    Ogale, Sarika
    Mahrus, Sami
    Murphy, John
    Wilson, Thomas W.
    Patton, Gregory A.
    Loaiza-Bonilla, Arturo
    Singal, Amit G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 447 - 447
  • [28] REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES
    Dayyani, Farshid
    Mhatre, Shivani
    Ferro, Ana
    Lawrance, Marcus
    Gaillard, Vincent
    Morse, Michael
    HEPATOLOGY, 2020, 72 : 650A - 651A
  • [29] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
    Ikeda, M.
    Kato, N.
    Kagawa, T.
    Yamashita, T.
    Moriguchi, M.
    Nakamura, S.
    Sawada, K.
    Iijima, H.
    Kamoshida, T.
    Nakao, K.
    Ohkawa, K.
    Sugimoto, R.
    Takehara, T.
    Harada, M.
    Yamamoto, Y.
    Ito, T.
    Kudo, M.
    Kokudo, N.
    Yamamoto, K.
    Furuse, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1467
  • [30] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
    Kuzuya, T.
    Yamashita, T.
    Takehara, T.
    Aikata, H.
    Kato, N.
    Hiasa, Y.
    Nakamura, S.
    Morimoto, N.
    Moriguchi, M.
    Ikeda, M.
    Inoue, J.
    Tani, J.
    Ueno, Y.
    Chayama, K.
    Tateishi, R.
    Kawamura, Y.
    Furuse, J.
    Kudo, M.
    Yamamoto, K.
    Kokudo, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1531 - S1532
12345